BACKGROUND: The vast majority of women diagnosed with ductal carcinoma in situ (DCIS) undergo treatment. Therefore, the risks of invasive progression and competing death in the absence of locoregional therapy are uncertain. METHODS: We performed survival analyses of patient-level data from DCIS patients who did not receive definitive surgery or radiation therapy as recorded in the US National Cancer Institute's Surveillance, Epidemiology, and End Results program (1992-2014). Kaplan-Meier curves were used to estimate the net risk of subsequent ipsilateral invasive cancer. The cumulative incidences of ipsilateral invasive cancer, contralateral breast cancer, and death were estimated using competing risk methods. RESULTS: A total of 1286 DCIS patients who did not undergo locoregional therapy were identified. Median age at diagnosis was 60 years (inter-quartile range = 51-74 years), with median follow-up of 5.5 years (inter-quartile range = 2.3-10.6 years). Among patients with tumor grade I/II (n = 547), the 10-year net risk of ipsilateral invasive breast cancer was 12.2% (95% confidence interval [CI] = 8.6% to 17.1%) compared with 17.6% (95% CI = 12.1% to 25.2%) among patients with tumor grade III (n = 244) and 10.1% (95% CI = 7.4% to 13.8%) among patients with unknown grade (n = 495). Among all patients, the 10-year cumulative incidences of ipsilateral invasive cancer, contralateral breast cancer, and all-cause mortality were 10.5% (95% CI = 8.5% to 12.4%), 3.9% (95% CI = 2.6% to 5.2%), and 24.1% (95% CI = 21.2% to 26.9%), respectively. CONCLUSION: Despite limited data, our findings suggest that DCIS patients without locoregional treatment have a limited risk of invasive progression. Although the cohort is not representative of the general population of patients diagnosed with DCIS, the findings suggest that there may be overtreatment, especially among older patients and patients with elevated comorbidities.
BACKGROUND: The vast majority of women diagnosed with ductal carcinoma in situ (DCIS) undergo treatment. Therefore, the risks of invasive progression and competing death in the absence of locoregional therapy are uncertain. METHODS: We performed survival analyses of patient-level data from DCIS patients who did not receive definitive surgery or radiation therapy as recorded in the US National Cancer Institute's Surveillance, Epidemiology, and End Results program (1992-2014). Kaplan-Meier curves were used to estimate the net risk of subsequent ipsilateral invasive cancer. The cumulative incidences of ipsilateral invasive cancer, contralateral breast cancer, and death were estimated using competing risk methods. RESULTS: A total of 1286 DCIS patients who did not undergo locoregional therapy were identified. Median age at diagnosis was 60 years (inter-quartile range = 51-74 years), with median follow-up of 5.5 years (inter-quartile range = 2.3-10.6 years). Among patients with tumor grade I/II (n = 547), the 10-year net risk of ipsilateral invasive breast cancer was 12.2% (95% confidence interval [CI] = 8.6% to 17.1%) compared with 17.6% (95% CI = 12.1% to 25.2%) among patients with tumor grade III (n = 244) and 10.1% (95% CI = 7.4% to 13.8%) among patients with unknown grade (n = 495). Among all patients, the 10-year cumulative incidences of ipsilateral invasive cancer, contralateral breast cancer, and all-cause mortality were 10.5% (95% CI = 8.5% to 12.4%), 3.9% (95% CI = 2.6% to 5.2%), and 24.1% (95% CI = 21.2% to 26.9%), respectively. CONCLUSION: Despite limited data, our findings suggest that DCIS patients without locoregional treatment have a limited risk of invasive progression. Although the cohort is not representative of the general population of patients diagnosed with DCIS, the findings suggest that there may be overtreatment, especially among older patients and patients with elevated comorbidities.
Authors: Meagan E Brennan; Robin M Turner; Stefano Ciatto; M Luke Marinovich; James R French; Petra Macaskill; Nehmat Houssami Journal: Radiology Date: 2011-04-14 Impact factor: 11.105
Authors: Yasuaki Sagara; Melissa Anne Mallory; Stephanie Wong; Fatih Aydogan; Stephen DeSantis; William T Barry; Mehra Golshan Journal: JAMA Surg Date: 2015-08 Impact factor: 14.766
Authors: Laura C Collins; Rulla M Tamimi; Heather J Baer; James L Connolly; Graham A Colditz; Stuart J Schnitt Journal: Cancer Date: 2005-05-01 Impact factor: 6.860
Authors: Lotte E Elshof; Konstantinos Tryfonidis; Leen Slaets; A Elise van Leeuwen-Stok; Victoria P Skinner; Nicolas Dif; Ruud M Pijnappel; Nina Bijker; Emiel J Th Rutgers; Jelle Wesseling Journal: Eur J Cancer Date: 2015-05-26 Impact factor: 9.162
Authors: Anna F Meyerson; Juan N Lessing; Kaoru Itakura; Nola M Hylton; Dulcy E Wolverton; Bonnie N Joe; Laura J Esserman; E Shelley Hwang Journal: Breast Date: 2011-08-16 Impact factor: 4.380
Authors: Irene L Wapnir; James J Dignam; Bernard Fisher; Eleftherios P Mamounas; Stewart J Anderson; Thomas B Julian; Stephanie R Land; Richard G Margolese; Sandra M Swain; Joseph P Costantino; Norman Wolmark Journal: J Natl Cancer Inst Date: 2011-03-11 Impact factor: 13.506
Authors: Jack Cuzick; Ivana Sestak; Sarah E Pinder; Ian O Ellis; Sharon Forsyth; Nigel J Bundred; John F Forbes; Hugh Bishop; Ian S Fentiman; William D George Journal: Lancet Oncol Date: 2010-12-07 Impact factor: 41.316
Authors: Marc D Ryser; Laura H Hendrix; Mathias Worni; Yiling Liu; Terry Hyslop; E Shelley Hwang Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-06-11 Impact factor: 4.254
Authors: Rui Hou; Maciej A Mazurowski; Lars J Grimm; Jeffrey R Marks; Lorraine M King; Carlo C Maley; Eun-Sil Shelley Hwang; Joseph Y Lo Journal: IEEE Trans Biomed Eng Date: 2019-09-09 Impact factor: 4.538
Authors: Ilona Fridman; Lok Chan; Jennifer Thomas; Laura J Fish; Margaret Falkovic; Jacquelyn Brioux; Nicole Hunter; Daniel H Ryser; E Shelley Hwang; Kathryn I Pollak; Kevin P Weinfurt; Marc D Ryser Journal: Breast Cancer Res Treat Date: 2022-02-02 Impact factor: 4.872